A Case of Mixed Neuroendocrine and Non-Neuroendocrine Neoplasms of the Esophagus with Rapid Progression of Postoperative Metastatic Recurrence Accompanying Trousseau’s Syndrome

Sakano, Yu; Nishikawa, Kazuhiro; Hamakawa, Takuya; Toshiyama, Reishi; Miyo, Masaaki; Takahashi, Yusuke; Miyake, Masakazu; Miyamoto, Atsushi; Kato, Takeshi; Mori, Kiyoshi; Hirao, Motohiro

doi:10.5833/jjgs.2021.0070

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Trousseau’s syndrome is the cancer-related thrombosis, and about 10% of all thrombotic events are arterial thrombosis, which have been observed in cerebral arteries and upper and lower limb arteries [9] . The case report of Trousseau’s syndrome in NEC was searched using PubMed, Scopus, CiNii, and J-STAGE from inception to November 2022 using the search terms “neuroendocrine carcinoma” and “Trousseau’s syndrome”, and one case report of Trousseau’s syndrome with advanced NEC of esophagus was found [10] . Anticoagulant therapy with low-molecular-weight heparin (LMWH) or unfractionated heparin has been reported to be effective for Trousseau’s syndrome [9] ; however, it has also been reported that significant recurrence of thrombosis occurs due to the discontinuation of heparin, making it difficult to discontinue anticoagulant therapy and long-term administration might be required [11] .…”

Section: Discussionmentioning

confidence: 99%

Trousseau’s Syndrome with Advanced Neuroendocrine Carcinoma of Colon: A Case Report

Ohmura¹,

Tobo²,

Mimori³

et al. 2023

Case Rep Oncol

View full text Add to dashboard Cite

Here, we present a 69-year-old female with advanced neuroendocrine carcinoma (NEC) of colon with multiple liver, bone, and kidney metastases who developed Trousseau’s syndrome. The patient received etoposide plus cisplatin (EP) as the first-line therapy; however, after single administration of EP, she developed the severe lower-limb edema and EP was considered to be intolerable. Etoposide plus carboplatin was administered as the second-line therapy and after 3 cycles of administration, the progressive disease (PD) was confirmed and 5-fluorouracil + leucovorin + irinotecan (FOLFIRI) plus ramucirumab was administered as the third-line therapy. However, PD was confirmed after 3 cycles of the therapy, and she was to receive the best supportive care and was hospitalized in our hospital. Four weeks after hospitalization, mild impaired consciousness and dysarthria were observed. Blood tests showed coagulation abnormalities including elevation of plasma fibrin/fibrinogen degradation products (FDPs) and D-dimer levels, and the diffusion-weighted image of magnetic resonance imaging (MRI) of the head showed multiple cerebral infarcts. She was diagnosed with Trousseau’s syndrome due to the progression of NEC and intravenous unfractionated heparin was administered as anticoagulant therapy. After the administration of heparin, plasma FDP and D-dimer levels decreased; however, due to the progression of NEC, the patient died 6 weeks after hospitalization. This is the first report of NEC of the colon that developed Trousseau’s syndrome.

show abstract